Bioventus Inc. (BVS) Misses Q2 EPS by 6c; Offers FY22 Guidance

Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.10, $0.06 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $140.3 million versus the consensus estimate of $138.33 million.

GUIDANCE:

Bioventus Inc. sees FY2022 EPS of $0.47-$0.57, versus the consensus of $0.65. Bioventus Inc. sees FY2022 revenue of $547.5-562.5 million, versus the consensus of $552 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy